Correspondence on Letter regarding “Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis”

Abstract

We sincerely appreciate the letter from Dr. Song, Chang, and Yang 1 for contemplating our recent paper on the prognostic impact of muscle mass change in outpatients with cirrhosis, published in Clinical and Molecular Hepatology. 2 We agree that sex and lifestyle influence muscle mass and that myosteatosis is an important prognostic marker in patients with cirrhosis.Many diagnostic criteria for sarcopenia have been established based on sex-specific differences, and this study was conducted by adopting one of them. However, the change in muscle mass may differ from the muscle mass itself. In our study, ΔSMI/yr%, which represented the change in muscle mass, was not an absolute value but a rate value divided by the muscle mass at inclusion.

PCDH7 as the key gene related to the co-occurrence of sarcopenia and osteoporosis

“…Sarcopenia is an aging syndrome characterized by decreased skeletal muscle mass, function, and strength ( Kim et al, 2022 ). The first practical clinical definition and consensus diagnostic criteria for it were developed in 2010 by the European Working Group on Sarcopenia in Older People (EWGSOP), and the consensus was updated in 2019 (EWGSOP2) ( Cruz-Jentoft et al, 2010 ; Cruz-Jentoft et al, 2019 ).…”